ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2344

Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study

Uta Kiltz1, Petros Sfikakis2, Andreas Bounas3, Nicola Gullick4, Eric LESPESSAILLES5, Jan Brandt Jürgens6, Rasho Rashkov7, Barbara Schulz8, Weibin Bao9, Piotr Jagiello10 and Karl Gaffney11, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 2Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 3PRIVATE PRACTICE, Patra, Greece, 4Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, 5CHR ORLEANS, ORLEANS, France, 6Rheumatologische Schwerpunktpraxis, Berlin, Germany, 7Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, 8GKM Gesellschaft für Therapieforschung mbH, Lessingstrasse, Munchen, Germany, 9Novartis Pharmaceuticals Corporation, East Hanover, NJ, 10Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, 11Health Care - NHS, Norwich, United Kingdom

Meeting: ACR Convergence 2024

Keywords: Ankylosing spondylitis (AS), Biologicals, Interleukins, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SpA Including PsA – Treatment Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Real-world data on long-term use of secukinumab complements clinical trial findings by providing insights from diverse patients in routine clinical settings. SERENA (CAIN457A3403) was a non-interventional, prospective study conducted across 19 primarily European countries for up to 5 years in patients with moderate to severe chronic plaque psoriasis, active psoriatic arthritis (PsA) or radiographic axial spondyloarthritis (r-axSpA), who had received secukinumab for ≥16 weeks before enrolment. Here, we report the final 5-year results of retention and effectiveness of secukinumab in patients with active PsA or r-axSpA from the study.

Methods: Secukinumab retention rate was derived from Kaplan-Meier estimates for the proportion of patients who had been treated with secukinumab at years 1, 2, 3, 4 and 5. Effectiveness assessments included swollen joint count (SJC) and tender joint count (TJC) in patients with PsA, Patient Global Assessment (PtGA) of disease activity of Numeric Rating Scale (NRS ≤2) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score in patients with r-axSpA, up to 5 years.

Results: Overall, 522 patients with PsA and 474 patients with r-axSpA were included in the analysis. The mean age at inclusion was 52.5 years in the PsA group and 46.5 years in the r-axSpA group, with 44.8% and 60.5% being male, respectively. Mean body mass index of 28.7 kg/m2 was observed in the PsA group and 27.0 kg/m2 in the r-axSpA group. Disease duration at enrolment was 8.6 ± 7.4 years in PsA and 9.8 ± 9.5 years in r-axSpA respectively. Overall, 68.6% and 64.6% of patients with PsA and r-axSpA had undergone bDMARDs (biologic disease-modifying antirheumatic drugs) treatment prior to secukinumab, respectively. Before inclusion in the study, the patients had been receiving secukinumab treatment for an average of 1 year. After inclusion in the study, the treatment retention rates at years 1, 2, 3, 4 and 5 for PsA group were 86.9%, 75.8%, 67.9%, 60.8% and 55.7%, respectively (Figure 1). Similarly, the treatment retention rates at years 1, 2, 3, 4 and 5 for r-axSpA group were 86.2%, 78.8%, 72.1%, 65.2% and 61.1%, respectively (Figure 1). The most common reasons for discontinuation in PsA and r-axSpA were lack of efficacy (27.2% and 17.7%, respectively), patient decision (11.9% and 8.6%), lost to follow-up (5.7% and 6.1%) and adverse events (3.1% and 7.2%). The proportion of patients with TJC ≤1 was 75.7% at year 1 and 81.0% at year 5; the proportion of patients with a SJC ≤1 response was 86.5% at year 1 and 90.0% at year 5 in the PsA group (Table 1).  BASDAI improved in r-axSpA group through the 5 years. The proportion of patients with PtGA NRS ≤2 was 32.5% at year 1 and 46.1% at year 5 in the r-axSpA group (Table 1).

Conclusion: Secukinumab retention rates were high with sustained effectiveness in patients with PsA and r-axSpA during 5-year follow-up in a prospective real-world setting.

Supporting image 1

Figure 1: Kaplan-Meier estimates of the retention rate of secukinumab in patients with PsA and r-axSpA from year 1 through year 5.
n, number of patients at risk, PsA, psoriatic arthritis, r-axSpA, radiographic axial spondylarthritis.

Supporting image 2

Table 1: Effectiveness responses with secukinumab in patients with PsA and r-axSpA from year 1 through year 5


Disclosures: U. Kiltz: AbbVie, 2, 5, 6, Amgen, 5, Biocad, 2, 6, Biogen, 5, Chugai, 2, 6, Eli Lilly, 2, 6, Fresenius, 5, 6, Grünenthal, 2, 6, GSK, 5, Hexal, 5, Janssen, 2, 6, MSD, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 6, UCB, 2, 6; P. Sfikakis: None; A. Bounas: AbbVie, 6, Aeonorasis, 6, Amgen, 6, Bausch Health, 6, FARAN, 6, Genesis Pharma, 6, GSK, 6, Janssen, 6, MSD, 6, Novartis, 6, Pfizer, 6, UCB, 6; N. Gullick: AbbVie, 5, 6, Eli Lilly, 5, 6, Janssen, 5, 6, Novartis, 5, 6, UCB, 5, 6; E. LESPESSAILLES: AbbVie, 5, 6, Amgen, 2, 5, 6, Eli Lilly, 2, 5, 6, Expanscience, 2, 6, Galapagos, 6, MSD, 2, 5, 6, Novartis, 5, UCB, 5; J. Brandt Jürgens: AbbVie, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Medac, 2, 6, MSD, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 2, 6, Sanofi-Aventis, 2, 6, UCB, 2, 6; R. Rashkov: AbbVie, 2, 6, Amgen, 2, 6, Janssen, 2, 6, MSD, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 6; B. Schulz: GKM Gesellschaft für Therapieforschung mbH, 3, Novartis, 12, Employee of GKM Gesellschaft für Therapieforschung mbH, Lessingstrasse, München, Germany and provides services to Novartis.; W. Bao: Novartis, 3, 11; P. Jagiello: Novartis, 3; K. Gaffney: AbbVie, 2, 5, 6, Eli Lilly, 2, 5, 6, Gilead, 5, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB Pharma, 2, 5, 6.

To cite this abstract in AMA style:

Kiltz U, Sfikakis P, Bounas A, Gullick N, LESPESSAILLES E, Brandt Jürgens J, Rashkov R, Schulz B, Bao W, Jagiello P, Gaffney K. Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/secukinumab-retention-and-effectiveness-in-patients-with-psoriatic-arthritis-and-radiographic-axial-spondyloarthritis-5-year-final-results-of-a-prospective-real-world-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/secukinumab-retention-and-effectiveness-in-patients-with-psoriatic-arthritis-and-radiographic-axial-spondyloarthritis-5-year-final-results-of-a-prospective-real-world-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology